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Abstract
Background: The ambiguous role of transcription factor Sp3 for tumour progression is still debated since it was described
as a transcriptional repressor or activator. Here we tried to decipher the molecular mechanisms implicated in Sp3
accumulation observed in aggressive tumours.
Methodology: We generated normal and tumour cell lines conditionally expressing Sp3. Cell growth was analyzed in vitro
and after inoculation in nude mice. Apoptosis was assessed by pan- caspase activity assays, by counting fragmented nuclei
and by determination of caspase 9 cleavage. Gene expression was determined by quantitative PCR. Cleavage by different
caspases was performed after in vitro translation of the Sp3 cDNA in the presence of [S
35] labelled methionine. Different
tumour cell lines and head and neck tumour samples were tested for the presence of Sp3 by western blots. Correlation
between Sp3 expression and overall survival has been statistically determined.
Principal Findings: Conditional over-expression of Sp3 induces apoptosis and modifies expression of genes implicated in
the regulation of cell cycle and pro and anti apoptotic genes. Sp3 over-expression strongly reduces the development of
tumours in nude mice confirming its pro-apoptotic potential in vivo. However, cells can survive to apoptosis through
selective Sp3 cleavage by caspase. Sp3 induction in established tumours resulted in transient regression then progression.
Progression coincides with re-accumulation of the full length form of Sp3. Sp3 is over-expressed in tumour cell lines of
different origins. The presence of high levels of the full-length form of Sp3 indicates a poor prognosis for overall survival of
patients with head and neck tumours.
Conclusions: Full length Sp3 accumulation highlights bypass of tumour cell apoptotic capacities and is indicative of head
and neck tumours aggressiveness.
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Introduction
Sp3 is a zinc finger transcription factor that belongs to the Sp
transcription factor family comprising Sp1, 2 and 4. Sp3 can act as
an activator or a repressor of transcription depending on
sumoylation processes [1]. It is expressed as a full-length
110 kDa protein but internal initiation of translation results in
shorter Sp3 isoforms [2]. The relationship between Sp1 and
tumourigenesis depends on the expression of genes implicated in
growth control, apoptosis resistance and angiogenesis [3].
Moreover, down-regulation of over-expressed Sp1 protein in
human fibrosarcoma cell lines inhibits tumour formation [4]. Sp1
is over-expressed in different types of tumour [5]. A relationship
between Sp3 and cancer has also been suggested in recent studies
[6] but has not been fully addressed. The above data have
demonstrated the importance of Sp1 and Sp3 for tumour
formation. However, over-expression of Sp1 results in apoptosis
in different cell types [7]. This is controversial since Sp1 and Sp3
protect cortical neurons against apoptosis [8] and induce genes
implicated in survival [9]. Moreover, betulinic acid, a natural
product with anti-tumour activity, induces apoptosis by degrading
Sp1 and Sp3 [10]. These data encouraged us to address the role of
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4478Sp3 in apoptosis and to evaluate its prognosis value in highly
aggressive head and neck tumours.
Results
Sp3 over-expression is detrimental for cell maintenance
The role of Sp3 in apoptosis regulation was analysed in Chinese
hamster lung fibroblasts (R443) and colon carcinoma cells (LS174)
conditionally expressing full-length Myc-tagged Sp3 [11]. Both
cells were chosen in order to determine the effect of Sp3 over-
expression in a normal and a tumour cell line. Figure 1 shows that
exogenous Sp3 was induced by tetracycline stimulation in the
different cell types. Two independent LS174 clones (clone 25 (S25)
and clone 27 (S27)) and one R443 clone conditionally expressing
Sp3 were tested. Western blot experiments with an anti-Sp3
antibody showed that exogenous Sp3 was over-expressed com-
pared to the endogenous form in both cell lines. Moreover,
endogenous Sp3 was more highly expressed in LS174 than in
R443 cells. Note that following over-expression, extra bands were
detected at 60 and 35 kDa with both anti-Sp3 and anti-Myc
antibodies. These bands were also observed in extracts from
control LS174 cells after a longer exposure. Figure 1 also shows
that overexpression of Sp3 do not significantly affect the Sp1
endogenous levels. Figure 2A shows that tetracycline induction of
Sp3 resulted in decreased accumulation of both R443 and LS174
cells in a time dependent manner. Figure 2B shows that lower
concentrations of tetracycline still induce cell death in R443 and
S27 cells. The same effects were observed at concentrations of 1 or
0.1 mg/ml tetracycline since induction of Sp3 is equivalent at such
concentrations as already described [11]. At a tetracycline
concentration of 0.01 mg/ml Sp3 levels are significantly decreased
while inexistent at 0.001 mg/ml.
Sp3 over-expression induces apoptosis
Prevention of cell accumulation can be attributed to cell cycle
arrest or induction of apoptosis. We carefully addressed the
apoptosis mechanisms by three independent methods: measure-
ment of pan-caspase activity, evaluation of the number of
fragmented nuclei and cleavage of caspase 9. Figure 3A shows
that induction of Sp3 resulted in increased pan-caspase activity.
The specific pan-caspase inhibitor Z-VAD-FMK inhibits both
basal and Sp3-dependent caspase activation which was stronger in
LS174 cells (clone S27), probably reflecting the higher basal
amounts of Sp3 in the absence of tetracycline. We have then more
carefully addressed the apoptotic potential of Sp3 in the LS174
tumour cells. A quantitative analysis of fragmented nuclei upon
Sp3 induction presented in Figure 3B illustrates that more than
50% cells were apoptotic following 72 hours of Sp3 induction and
that the increased number of apoptotic cells paralleled the
cleavage/activation of caspase 9 and PARP cleavage (Figure 3C),
two substrates for active caspase 3 [12]. Sp3 effects on cell
accumulation are partially inhibited by the pan-caspase inhibitor
Z-VAD-FMK indicating that Sp3 induces a caspase-dependent
apoptosis. Such reversion is coherent with the results of Deniaud et
al who has observed the same effects of Z-VAD-FMK on Sp1-
induced apoptosis [7]. Also note that Z-VAD-FMK treatment by
itself results in cell accumulation suggesting that the basal caspase
activity observed in figure 3A has been inhibited. Altogether our
data clearly show that Sp3 over-expression is pro-apoptotic.
Gene expression in Sp3-inducible LS174 cells
The involvement of Sp3 in cell death was further evaluated by
testing the expression of different specific transcripts involved in
apoptosis and survival. We focused on a limited number of major
pro- or anti-apoptotic genes (88) (File S1). Of these, 11 were up-
regulated and only one (Bcl-2) was down-regulated. Figure 4
shows that both pro- (TGF b, GADD45, MyD88, DR3, Puma,
Fas caspase 9) and anti-apoptotic (Egr-1, IEX-1, STAT-5, Bcl2)
genes were modulated by Sp3. p21/WAF1 is not directly
implicated in apoptosis but regulates cell cycle. Regulation of
p21/WAF1 by Sp3 has already been described [13]. It suggests
that the decrease in cell number observed in figure 2 is a
combination of Sp3-induced apoptosis and cell cycle arrest. Since
p27 expression is induced upon Sp3 down-regulation by siRNA
[14] we have tested its amounts in both R443 and LS74 cells upon
Sp3 induction. No modifications were observed in both cell lines
(File S2). This complex set of regulated genes may explain the
contradictory functions of Sp3 in the regulation of cell death and
cell growth.
Sp3 is a caspase substrate
After extensive apoptosis, a few cells became progressively
resistant to Sp3 induction. Figure 5A shows the two main Sp3
degradation products of 60 and 35 kDa (cleaved product 1 and 2,
(CP1, CP2)) detected with the Myc antibody in all the resistant
clones. This suggests a cleavage mechanism at specific proteolytic
sites. Note that both fragments were observed in control cells at a
Figure 1. Western blot analysis of Sp3 expression in R 443 and
LS 174 cells. Control R443 and LS174 cells (C) or their derivatives
expressing Sp3 (S for R443 and S25 and S27 for LS174) were cultivated
in the presence or absence of tetracycline for 24 hours and analysed for
the presence of Sp3 by using Sp3- (Ab Sp3, D20 Santa Cruz, CA) and
Myc-directed antibodies (Ab Myc, 9E10). The Sp1 levels were also
analysed by using a Sp1 specific antibody (PEP-2, Santa Cruz, CA). Total
Erk2 is shown as a loading control. This experiment is representative of
three independent experiments.
doi:10.1371/journal.pone.0004478.g001
Sp3 and Apoptosis
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of LS174 cells (Figure 1). In vitro cleavage assays on in vitro
translated protein (Figure 5B) or on cell extracts from tetracycline-
induced cells (Figure 5C) demonstrated that Sp3 is cleaved by
caspase 3 and/or caspase 6 but not caspase 7. Such cleavage
generates two fragments equivalent to those detected by western
blot in control and tetracycline-resistant clones. Our results
strongly suggest that Sp3 is a caspase substrate.
Sp3 induction prevents tumour formation in nude mice
LS174 cells conditionally expressing Sp3 were sub-cutaneously
injected into nude mice. Figure 6A shows that injection of LS174 cells
resulted in the formation of tumours two weeks following inoculation.
Doxycycline-mediated induction of Sp3 prevented tumour develop-
ment throughout the 60 days of follow-up. Only one mouse out of
twelve developed a tumour upon doxycycline treatment. Western blot
analysis revealed the absence of full-length Sp3 and the presence of
Figure 2. Inducible expression of Sp3 is detrimental for cell accumulation. A) Cells were cultivated in the presence or absence of
tetracycline (1 mg/ml) and counted every day for three days. Each day, cell number in absence of tetracycline was taken as the reference value (100%).
The percentage of cells remaining in the presence of tetracycline is plotted. For LS174 cells, two independent clones (S25 and S27) expressing
different amounts of Sp3 were evaluated. For R443 cells, a previously described representative clone [11] was compared to control cells. These results
are the mean of three independent experiments. Significant modifications (* p,0.05) are indicated. B) R443/Sp3 cells and LS174 cells (S27) were
incubated in the absence (0) or in the presence of the indicated tetracycline concentrations for 72 hours. Cell amount in the absence of tetracycline
was taken as the reference value (100%). The percentage of cells remaining in the presence of tetracycline is plotted. These results are the mean of
three independent experiments. Significant modifications (* p,0.05) are indicated.
doi:10.1371/journal.pone.0004478.g002
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PLoS ONE | www.plosone.org 3 February 2009 | Volume 4 | Issue 2 | e4478Figure 3. Sp3 over-expression induces apoptosis. Cells described in Figure 1 were tested for Sp3-mediated apoptosis by different methods. A)
Pan-caspase activity was measured in R443 and LS174 cells expressing Sp3 (S27 for LS174) in the presence or absence of 50 mM Z-VAD-FMK as
indicated in materials and methods. Results are the mean of three independent experiments performed in duplicate and significant modifications (*
p,0.05) are indicated. B) Control or Sp3 expressing LS174 (S27) cells were cultivated in the absence (2Tet) or presence (+Tet) of tetracycline then
stained with DAPI. At least ten photographs for each condition (twenty nuclei per photograph) were examined for the presence of fragmented nuclei.
The percentage of cells with fragmented nuclei is plotted. The results are representative of three independent experiments. A significant increase of
cell number with fragmented nuclei (* p,0.05) is indicated. C) Western blot analysis of caspase 9 (sc-7885, Santa Cruz, CA antibody) and PARP (C2-10,
Santa Cruz, CA antibody) in LS174 or LS174 cells expressing Sp3 (S27) treated with (+) or without (2) tetracycline. The caspase 9 and PARP cleaved
fragments (cC9 and cPARP respectively) are indicated by arrows. Erk2 is shown as a loading control. The results are representative of three
independent experiments. D) LS174 cells expressing Sp3 (S27) were incubated overnight in the presence or absence of tetracycline (1 mg/ml)
supplemented or not with 50 mM of Z-VAD-FMK. Cell number in absence of tetracycline and Z-VAD-FMK was taken as the reference value (100%). The
percentage of cells remaining in the absence (2) or presence (+) of tetracycline supplemented or not with Z-VAD-FMK is plotted. These results are the
mean of two independent experiments. Significant modifications (* p,0.05) are indicated.
doi:10.1371/journal.pone.0004478.g003
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Sp3-mediated cell death was bypassed by Sp3 cleavage. Interestingly,
Sp3 induction in established tumours resulted in regression at first, but
after two weeks progression was observed. Analysis of tumour extracts
from tumours in the progression phase revealed the presence of Sp3
degradation products CP1 and CP2, but small amounts of exogenous
full-length Sp3 were also detectable (Figure 6B, lanes 6 to 9,
Cont+DOX). As expected, the full length form of Sp3 was
undetectable in extracts from tumours that have grown in the absence
o fd o x y c y c l i n e( F i g u r e6 B ,l a n e s1t o4 ,C o n t ) .S p e c i f i cp a nc a s p a s e
activity in the control tumours and in the tumours that have grown in
the presence of doxycycline (Figure 6C) is at least ten times lower than
in the original cells (see figure 3A). Moreover, pan caspase activity has
a trend to be superior in the control tumours than in tumours that
have grown in the presence of doxycycline (Figure 6C, p=0.084).
These results suggest in vivo selection of mutant tumour cells with less
caspase activity than the original cells. This lower caspase activity
highlighted by Sp3 accumulation is a hallmark of aggressive tumour
cells. In the adapted cells, full-length active Sp3 could stimulate
transcription of genes involved in activation of the cell cycle [15] and
angiogenesis [11]. Hence, the observed tumour progression could be
the result of decrease apoptotic capacity and increased proliferation
and angiogenic potential of the adapted cells.
The presence of full-length Sp3 in head and neck
tumours is an independent prognostic factor for overall
survival
The relevance of Sp3 expression for tumour aggressiveness was
first evaluated in different tumour cell lines. Sp3 was more highly
expressed in tumour than in normal cell lines (fibroblast, endothelial
cells) (Figure 7A). We then tried to extrapolate these results to
humanheadandneckcarcinomas(H&N).Asincoloncancer,H&N
tumours have mutations in ras and over-expression of EGF
receptors leading to activation of the ERK pathway. We
unsuccessfully tried to constitutively express Sp3 in H&N tumour
cells,suggestingthatthepro-apototicpotentialofSp3 isalsoefficient
in thesecells. Sp3 levelsin 52 H&N tumoursamples were previously
analysed by our team [16]. The median follow-up for all patients
was60 months.Table 1 and Figure7Bshowthat Sp3 expression is a
factor of poor prognosis for overall survival (p=0.043). Moreover,
patient age, tumour size and nodal status were also significantly
correlated with overall survival (p,0.05) and serve as positive
controls. A multivariate Cox regression model showed that Sp3
expression is an independent prognosis parameter for overall
survival (Table 2, p=0.038). Western blot analysis on 16 tumours
samples shows that Sp3 and Sp1 follow the same expression profile
(low expression of Sp3/low expression of Sp1; high expression of
Sp3/high expression of Sp1) which is consistent with the prognostic
role of Sp1 described for other tumour types (File S3). It is
interesting to note that the amount of CP2 in human and
experimental tumours upon progression (Figure 6B) is more
abundant than in cells stimulated by tetracycline for a few hours.
This suggests that the phenomenon of adaptation has been induced
progressively after a first round of degradation by caspases.
Discussion
Identification of new prognostic markers for tumour aggres-
siveness is important for optimising treatments. For this reason we
Figure 4. Gene expression profile in cells with conditional Sp3 expression. Expression of 88 pro- and anti-apoptotic genes was tested in
LS174 cells conditionally expressing Sp3 (S27) by real time PCR. The variations of the significantly modified genes (* p,0.05) are represented. The
mean fold increase6SD of three independent experiments performed in triplicate, is plotted.
doi:10.1371/journal.pone.0004478.g004
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indicator of tumour aggressiveness. Our study was based on
previous observations describing Sp1 as an indicator of poor
prognosis for pancreatic cancers [17]. However, the Shi et al study
was contradicted by the results of Deniaud et al. [7], which showed
that Sp1 over-expression induces apoptosis. Although it is over-
expressed in tumour cells and tumour samples, Sp3 also induces
apoptosis. One part of the puzzle has been elucidated since
increased Sp3 expression seems progressive from benign to
aggressive tumours [18]. The present data have highlighted that
accumulation of Sp3 is progressive all along the tumour process.
This mechanism of adaptation apparently depends on a balance
between reduced of Sp3 cleavage and increased Sp3 expression
and/or stability. Hence, the presence of the full-length active form
of Sp3 results in increased transcription of many genes related to
tumour growth [19] and angiogenesis [11]. The use of an
inducible cellular system has allowed evaluation of the initiation of
apoptosis related to Sp3 accumulation, a mechanism mimicking
the first steps that potentially happen in vivo. In the case of tumour
development, Sp3 could first be considered as a tumour suppressor
during the initial steps, then as an oncogene, since it boosts growth
and angiogenesis. Accumulation of Sp3 could be the result of
increased ERKs activity since ERKs-induced Sp3 phosphorylation
results in increased half-life [11]. The initiation of tumour
development by oncogenes would allow adjustment of Sp3 levels,
thus controlling the balance between growth and apoptosis. The
latter (i.e. apoptosis) has been addressed by evaluating the genes
activated upon Sp3 induction. Only 12 genes were modulated.
While TGFb [20], Egr1 [21], p21 [13], IEX1 [22], STAT5 [23],
PUMA [24], FAS [25], BAK [26], Caspase 9 [27] and Bcl2 [28]
contain active Sp3 binding sites in their promoters suggesting direct
regulation, GADD45 (a target of p53 [29] and FOXO [30]) and
MyD88 (a target of STAT-1 and IRF-1 [31]) do not, suggesting
indirect regulation. Since TGFb was maximally induced upon Sp3
overexpression and because its role on apoptosis was highly
described, we tried to inhibit its action with blocking antibodies.
No modification was observed suggesting that it is not the ‘‘master
factor’’ implicatedinSp3-dependent apoptosis. Thecell growthstep
of the mechanism has been addressed in two ways: 1) the possibility
of obtainingcells resistant to Sp3-inducedapoptosis through specific
cleavage by caspase; the presence of a putative consensus cleavage
site (DSSD) in the Sp3 sequence supports our results but the
cleavage at this specific site needs to be confirmed; 2) formation of
tumours in nude mice has highlighted in vivo selection processes.
After an initial regression phase, a progression phase is observed.
This progression coincides with an accumulation of the full-length
form of Sp3. We hypothesised that the two phases observed in mice
mimic the process which happens in human tumours resulting in in
vivo selection of aggressive tumour cells with decrease apoptotic
potential and increased growth and angiogenic capacities.
Figure 5. Sp3 is a caspase substrate. A) Analysis by western blot of the exogenous form of Sp3 in tetracycline-induced S27 cells (24 hours) and in
clones chronically cultivated in the presence of tetracycline (1 to 9) with the Myc antibody. Arrows indicate the different reactive bands
corresponding to the full-length protein (FL) or cleavage products (CP 1 and CP 2). Erk2 is shown as a loading control. This result is representative of
two independent experiments. B) In vitro cleavage by caspase 3, 6 or 7 (BD Biosciences, Pharmingen) in the presence or absence of 50 mM Z-VAD-
FMK of in vitro-translated Sp3. Cleavage products are indicated by asterisks. C) In vitro cleavage by caspase 3 in the presence or absence of 50 mMZ -
VAD-FMK of Sp3 from tetracycline-stimulated LS174 cells (S27). The presence of cleaved products was analysed by western blot using an anti-Sp3
antibody. Cleaved products are indicated by asterisks. Erk2 is shown as a loading control.
doi:10.1371/journal.pone.0004478.g005
Sp3 and Apoptosis
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Sp3 in H&N tumours. Nevertheless, our study deserves to be
extended to a greater number of samples and to different types of
tumours.
Materials and Methods
Materials
Restriction and DNA-modifying enzymes and synthetic oligo-
nucleotides were from Eurogentec (Liege, Belgium). Anti-Myc
antibody (9E10), Anti-Sp1 (PEP-2) and Sp3 (D 20) were from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Erk 2 was a
home-made antibody [32].
Cell culture and transfection
Raf:ER (R443) and LS174 cells conditionally expressing Sp3
were generated and cultivated as previously described [11]. CCL
39 cells (CCL, hamster fibroblasts), human fibroblasts (Hu.Fi),
mouse embryo fibroblasts (MEF), DLD1 (colon adenocarcinoma),
HT1080 (fibrosarcoma), MDA MB231 (metastatic breast cancer),
PC3 (metastatic prostate cancer), SW480 (colon adenocarcinoma)
were cultivated as LS174 cells. U937 cells (lymphoma) were
cultivated in RPMI supplemented with 10% FCS, penicillin
(50 units/ml), and streptomycine sulphate (50 mg/ml). Human
microvascular endothelial cells (Hu.MEC) were kindly provided by
Dr Ellen Van Obberghen-Schilling. For cell proliferation
experiments, 5610
4 cells seeded in 12-well dishes were treated
with/without tetracycline for the indicated times and counted
using a Coulter counter (Beckman, Paris, France). Each value
Figure 6. Sp3 prevents tumour formation in nude mice. A) Nude
mice were inoculated with cells conditionally expressing Sp3 (LS174
clone S27). Comparison of the size of the tumours in animals receiving
doxycycline in drinking water (DOX) or normal water (Cont). 37 days
following inoculation, half of the control mice were treated with
doxycycline (Cont+DOX). Tumour size was measured at the indicated
times and tumour volume was calculated and plotted6SD. Statistically
significant differences (p,0.05) between controls and doxycycline
treated mice (*, immediate treatment after inoculation; **, treatment
after development of the tumours) are indicated. B) Analysis by western
blot with a Myc-directed antibody of extracts from tumours that have
grown without tetracycline (Cont, lanes 1 to 4), a tumour that had
grown in the presence of tetracycline (Cont’, lane 5) and from tumours
that had re-grown after tetracycline treatment of control tumours
(Cont+DOX, lanes 6 to 9). Myc-tagged Sp3 expression was also analysed
in S27 cells (Cells) treated (+, lane 11) or not (2, lane 10) by tetracycline.
Arrows indicate the position of the full-length (FL) and cleaved Sp3
fragments (CP 1 and CP 2). Erk2 is shown as a loading control. C) Pan-
caspase activity was measured in control tumours (Cont, black
histogram) and in tumours that have grown in the presence of
doxycycline (Cont+DOX, white histogram). Plotted is the specific
caspase activity (total activity minus the values in the presence of
50 mM Z-VAD-FMK) measured as indicated in materials and methods.
Results are the mean of three independent measurements of the
individual tumour extracts.
doi:10.1371/journal.pone.0004478.g006
Figure 7. Sp3 is an independent prognosis factor for overall
survival. A) Different normal (CCL, Hu.Fi, Hu.MEC, MEF) and tumour
cells (DLD1, HT1080, LS174, MDA, PC3, SW480, U937) were analysed by
western blot for their Sp3 content. The relative amounts of Sp3 are
plotted. This experiment is representative of two independent
experiments. B) Kaplan-Meier analysis of overall survival in patients
with head and neck tumours in relation to their full-length Sp3
expression level (p=0.043).
doi:10.1371/journal.pone.0004478.g007
Sp3 and Apoptosis
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final concentration of 1 mg/ml for each experiment.
Preparation of RNA and gene array analysis by real-time
quantitative PCR
1 mg of total RNA was reverse transcribed using random
priming and Superscript II reverse transcriptase (Invitrogen). Real-
time PCR was performed in an ABI PRISM 5700 Sequence
Detector System (Applied Biosystems, Courtaboeuf, France) using
the SYBR Green detection protocol and a dedicated ‘‘apoptosis
plaque’’ (Applied Biosystems, Courtaboeuf, France) containing the
major genes regulated upon apoptosis (see supporting information
File S1). The relative expression level of target genes was
normalized for RNA concentrations with four different house-
keeping genes (GAPDH, b-actin, HPRT and ubiquitin). mRNA
values are expressed as arbitrary units and represent the
mean6SD of duplicates of two independent experiments. The
sequences of the oligos corresponding to each gene tested in our
study can be recovered on applied technology internet site
(https://products.appliedbiosystems.com).
Measurement of caspase activity
Each assay (in triplicate) was performed with 50 mg of protein
prepared from control cells or cells stimulated with tetracycline as
previously described [33]. Briefly, cellular extracts were incubated
in a 96-well plate, with 0.2 mM of Ac-DEVD-pNa. Specific
caspase activity was measured at 405 nm in the presence or the
absence of 50 mM of the pan-caspase inhibitor Z-VAD-FMK.
Caspase activity is expressed in nmoles of paranitroaniline released
per min and per mg of protein. The same lysates were used for
determining caspase 9 cleavage using a polyclonal antibody (sc-
7885, Santa Cruz, CA) and poly (ADP-ribose) polymerase (PARP)
using a monoclonal antibody (C2-10, Santa Cruz, CA).
Measurement of fragmented nuclei
Cells were fixed with 5% paraformaldehyde in PBS (137 mM
NaCl, 2.68 mM KCl, 1.47 mM KH2PO4, 8.1 mM Na2HPO4,
pH 7.4). Morphological changes were observed using fluorescence
microscopy under U excitation (330–380 nm) and photographed
by a cooled CCD camera after staining with 0.5% (w/v) DAPI.
For each condition, at least ten photographs were examined
(twenty nuclei per photograph) and the number of fragmented
versus entire nuclei recorded. The number of cells with
fragmented nuclei was expressed as a percentage of total cells
counted.
In vitro caspase cleavage assays
Following subcloning of Sp3 cDNA into the pCDNA3 vector
[11] it was translated in vitro and cleaved with recombinant
caspases (BD PharMingen; San Diego, CA, USA) as previously
described [34]. Long and short forms of Sp3 can be produced
from this cDNA. The effect of the pan-caspase inhibitor Z-VAD-
FMK (50 mM) was also monitored in vitro. The same protocol was
Table 1. Univariate analysis on overall survival of all patients according to age, clinical stage, nodal status and Sp3 expression.
Variable Nb. of patients Nb. of deaths Median survival time (months) p-value
Patient age 0.045*
#70 years 46 27 41.7
.70 years 6 5 9.1
Tumour size 0.023*
T1–T2 16 6 Not reach
T3–T4 36 26 21.1
Nodal status 0.0083*
N0 16 5 Not reach
N+ 36 27 23.2
Sp3 expression 0.043**
#median 26 14 49.2
.median 26 18 17.8
*Log-Rank test.
**Peto and Peto modification of the Gehan-Wilcoxon test.
doi:10.1371/journal.pone.0004478.t001
Table 2. Multivariate analysis (Cox Model) on overall survival
of all patients.
Variable Nb. of patients HR 95% CI of HR p-value
Patient age
#70 years 46 Ref. Ref. 0.020
.70 years 6 1.19 [1.20–9.08]
Tumour size
T1–T2 16 Ref. Ref. 0.13
T3–T4 36 0.70 [0.81–5.01]
Nodal status
N0 16 Ref. Ref. 0.021
N+ 36 1.15 [1.19–8.44]
Sp3 expression
#median 26 Ref. Ref. 0.038
.median 26 2.15 [1.04–4.42]
HR: Hazard ratio.
CI: Confidence interval.
Ref.: Reference.
doi:10.1371/journal.pone.0004478.t002
Sp3 and Apoptosis
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24 hours. Following caspase treatment, proteins were run on 10%
polyacrylamide gels.
In vivo growth experiments and analysis of tumour
parameters
Animal experiments were performed in accordance with the
regulations of our institute’s ethics committee. LS174 cells
conditionally expressing Sp3 were injected subcutaneously into
the flank of 6 week-old nude (nu/nu) mice (Harlan, Gannat,
France). Doxycycline (750 mg/ml) was added to the drinking water
from day 3 after the injection or when tumour volume reached an
average of 600 mm
3. Care of the animals was provided according
to institutional guidelines: European Directive 86/609/EEC.
Cell extracts and tumour sample analysis
50 mg of whole cell extracts from the different cell types or
cytosolic extracts from tumour homogenates [16] were subjected
to western blotting using anti-Sp3 (D 20, Santa Cruz, CA). The
level of Sp3 in each cell or tumour sample was quantified with a
GeneGnome imaging system (Syngene, Frederick, MD, USA) and
normalised to the signals of b-actin and Sp3 present in LS174 cell
extracts.
Statistics
Quantitative data were analysed using one-way ANOVA. Data
were expressed as means6SEM. P,0.05 was considered to be
significant. For tumour analysis, all categorical data were
described using numbers (n.) and percentages (%). Quantitative
data were presented using median and range or mean and
standard deviation. Censored data were described using Kaplan
Meier estimation including median survival, and 95% confidence
intervals (95% CI). Statistical analysis was two-sided and
performed using R-2.5.0 for Windows. For univariate analysis,
statistical comparisons were performed using the Chi-squared test
or Fisher exact test for categorical data, the Student T test or
Wilcoxon test for quantitative data, and Log-Rank test or Peto and
Peto modification of the Gehan-Wilcoxon test for censored data.
Multivariate analysis was performed by creating a Cox propor-
tional hazards model. All variables associated with p,0.05 in the
univariate analysis were included in the model. Proportional
hazards tested for all entered variables using graphical (Schoenfeld
residuals, log-log plot of cumulative hazard) and statistical
methods. The search for interactions was automated using the
R-2.5.0 stepAIC procedure, with interactions considered signifi-
cant if p,0.01. Overall survival (OS) was defined as the interval
between first diagnosis of cancer and death related to any cause.
Follow-up was limited to 60 months for all patients. Patients lost to
follow-up were censored after 60 months or at the date of their last
known contact.
Supporting Information
File S1 List of the investigated genes
Found at: doi:10.1371/journal.pone.0004478.s001 (0.05 MB
DOC)
File S2 Sp3 overexpression do not affect p27 expression. Control
R443 and LS 174 cells (C) or their derivatives expressing Sp3 (S
and S 27 for LS 174) were cultivated in the presence or absence of
tetracycline for 24 hours and analysed for the presence of full-
length form of Sp3 (FL Sp3) and p27 (Ref antibodies;K25020,-
Transduction Laboratories (Mississauga, ON,Canada)).Total Erk
2 is shown as a loading control. This experiment is representative
of two independent experiments.
Found at: doi:10.1371/journal.pone.0004478.s002 (0.91 MB TIF)
File S3 Expression of Sp3 and Sp1 in head and neck tumour
samples. Analysis by western blot of tumour samples included in
the statistical analysis. Arrows indicate the position of full-length or
Sp3 cleaved fragments (FL, CP 1 and CP 2). Full length form of
Sp1 (100 kDa) is indicated by arrows. Note the presence of Sp1
isoform of lower molecular weight. Actin is shown as a loading
control.
Found at: doi:10.1371/journal.pone.0004478.s003 (1.09 MB TIF)
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